reports
Norwegian Cruise Line Holdings Reports Third Quarter 2025 Financial Re...
Norwegian Cruise Line Holdings Reports Third Quarter 2025 Financial Results Company delivers record quarterly revenue, meets or exceeds all guidance metrics Full year 2025 earnings outlook raised MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd. (“NCLC”), “Norwegian Cruise Line Holdings”, “Norwegian”, “NCLH” or the “Company”) today reported financial results for the third quarter ended September 30, 2025, and provided guidance for the fourth quarter and full year 2025. Highlights Achieved a quarterly record wi...
Norwegian Cruise Line Holdings Ltd. Donates Up to $100,000 to the Amer...
Norwegian Cruise Line Holdings Ltd. Donates Up to $100,000 to the American Red Cross to Support Relief Efforts for Communities Impacted by Hurricane Melissa MIAMI, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH), a leading global cruise company operating the Norwegian Cruise Line®, Oceania Cruises®, and Regent Seven Seas Cruises® brands, today announced a donation of up to $100,000 to support relief efforts following the devastating impact of Hurricane Melissa. The company will immediately donate $50,000 to the American Red Cross and will match up to a...
Humacyte Announces Publication of New Data Comparing Symvess™ to Autol...
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma - Results published in AAST’s Trauma Surgery & Acute Care Open Journal - - Study compared outcomes of patients treated with Symvess with patients in PROOVIT registry who were treated with vein - - In a comparison to prior results in the PROOVIT registry, outcomes for Symvess and autologous vein were similar for treatment of vascular trauma - DURHAM, N.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company develop...
Treace to Report Third Quarter 2025 Financial Results on November 6, 2...
Treace to Report Third Quarter 2025 Financial Results on November 6, 2025 PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, November 6, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in...
Norwegian Cruise Line Holdings to Hold Conference Call on Third Quarte...
Norwegian Cruise Line Holdings to Hold Conference Call on Third Quarter 2025 Financial Results MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., “Norwegian Cruise Line Holdings” or the “Company”) announced today it will report third quarter 2025 financial results on Tuesday, November 4, 2025 at 6:30 a.m. Eastern Time with a conference call and webcast to discuss results at 8:00 a.m. Eastern Time. The conference call will be webcast via the Company’s Investor Relations website, . A replay of the webcast will be a...
Norwegian Cruise Line Holdings and Repsol Sign Long-Term Agreement to ...
Norwegian Cruise Line Holdings and Repsol Sign Long-Term Agreement to Supply Renewable Fuels in Barcelona This 8-year collaboration positions both companies at the forefront of the energy transition within the cruise and maritime sectors MIAMI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) and Repsol today announced a landmark 8-year agreement to supply renewable marine fuels at the Port of Barcelona, establishing an unprecedented long-term relationship within the cruise industry. Beginning in the 2026 European season, Repsol will offer a portfolio ...
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered ...
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering DURHAM, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it entered into a securities purchase agreement with certain fundamental institutional investors to purchase approximately $60.0 million worth of its common stock and warrants in an oversubscribed registered direct offering. Under the terms of the securities purchase agree...
Humacyte Announces Publication of Long-Term Results for Ukrainian Pati...
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™ - Results published in Oxford Academic’s Military Medicine Journal - - After up to 18 months of follow-up patients were observed to have zero infections, amputations or deaths and a high rate of patency - DURHAM, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication in Oxford Acade...
Moody's Ratings downgrades Leggett & Platt to Baa3; outlook stable
Moody's Ratings (Moody's) downgraded Leggett & Platt, Incorporated's (Leggett & Platt) senior unsecured notes ratings to Baa3 from Baa2, senior unsecured MTN (medium-term note) program ratings to (P)Baa3 from (P)Baa2, and commercial paper rating to Prime-3 from Prime-2. The outlook changed to stable...
Leggett & Platt Announces 3Q 2025 Earnings Call
Leggett & Platt Announces 3Q 2025 Earnings Call Carthage, MO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Leggett & Platt (NYSE:LEG), a diversified manufacturer of engineered products serving several major markets, will release third quarter earnings results on Monday, October 27, 2025 after the market closes, and hold its quarterly conference call to discuss third quarter results, annual guidance, market conditions, company initiatives, and related matters on Tuesday, October 28, 2025, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). This call will be webcast and can be accessed from the Inve...
Norwegian Cruise Line Holdings Ltd. Launches Loyalty Status Honoring P...
Norwegian Cruise Line Holdings Ltd. Launches Loyalty Status Honoring Program Across All Three Brands Elevating recognition and rewarding brand loyalty, Norwegian Cruise Line Holdings Ltd. unlocks more ways for guests to explore the world across its three award-winning brands: Norwegian Cruise Line®, Oceania Cruises®, and Regent Seven Seas Cruises® MIAMI, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH), a leading global cruise company operating Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises, today announced the launch of its new ...
Humacyte Announces Expansion of Intellectual Property for Pipeline Pro...
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus – Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into 2041 for the composition of novel bioengineered esophagus – DURHAM, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at c...
Humacyte Announces Publication of Preclinical Data on Use of the CTEV ...
Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG) - Results were published in JACC: Basic to Translational Science - - Publication evaluated coronary tissue engineered vessel (CTEV) as a conduit for CABG in a nonhuman primate model - - All implanted CTEVs remained patent through six months, demonstrated adaptive remodeling, and recellularized with host coronary artery cells – - Humacyte plans to advance CTEV into first-in-human study in CABG - DURHAM, N.C., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a ...
Humacyte Announces Publication of Outcomes for Patients with Hospital-...
Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™ - Results were published in the Journal of Vascular Surgery - - Publication described treatment of patients with Symvess who had hospital-acquired iatrogenic injuries or complications of vascular surgical procedures - - Patients treated with Symvess were observed to have high levels of patency, 100% limb salvage, and zero cases of conduit infection - DURHAM, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biot...
NCL Corporation Ltd. Announces Expiration, Pricing Terms and Results o...
NCL Corporation Ltd. Announces Expiration, Pricing Terms and Results of its Debt Tender Offer MIAMI, Sept. 12, 2025 (GLOBE NEWSWIRE) -- NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (“NCLH”), today announced the expiration and results of its previously announced cash tender offer (the “Tender Offer”) to purchase any and all of its outstanding (i) 5.875% Senior Secured Notes due 2027 (the “2027 Notes”) and (ii) 5.875% Senior Notes due 2026 (the “2026 Notes” and, collectively with the 2027 Notes, the “Notes” and each a “Series” of Notes). Th...
Treace Highlights New Product Innovations and Updated Positive Clinica...
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2025 American Orthopaedic Foot & Ankle Society Annual Meeting PONTE VERDE, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and MTA3D™ clinical studies at the American Orthopaedic Foot & Ankle Society (AOFA...
NCL Corporation Ltd. Announces Upsizing and Pricing of $1,300.0 Millio...
NCL Corporation Ltd. Announces Upsizing and Pricing of $1,300.0 Million of Exchangeable Notes MIAMI, Sept. 09, 2025 (GLOBE NEWSWIRE) -- NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (“NCLH”), announced today that it has priced $1,300.0 million aggregate principal amount of its 0.750% exchangeable senior notes due 2030 (the “Exchangeable Notes”), which were offered in a private offering (the “Exchangeable Notes Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The ...
Norwegian Cruise Line Holdings Ltd. Announces Pricing of 3,313,868 Ord...
Norwegian Cruise Line Holdings Ltd. Announces Pricing of 3,313,868 Ordinary Shares MIAMI, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (the “Company”) announced today that it has priced its registered direct offering of 3,313,868 ordinary shares of the Company (the “Equity Offering”) to certain holders of NCL Corporation Ltd.’s (“NCLC”), a subsidiary of the Company, 1.125% Exchangeable Senior Notes due 2027 and 2.50% Exchangeable Senior Notes due 2027 (collectively, the “2027 Exchangeable Notes”) at a price of $24.53 per share. The Equity Offering i...
NCL Corporation Ltd. Announces Pricing of $2,050.0 Million of Senior N...
NCL Corporation Ltd. Announces Pricing of $2,050.0 Million of Senior Notes MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (“NCLH”), announced today that it has priced $1,200.0 million aggregate principal amount of its 5.875% senior notes due 2031 (the “2031 Unsecured Notes”) and $850.0 million aggregate principal amount of its 6.250% senior notes due 2033 (the “2033 Unsecured Notes” and, collectively with the 2031 Unsecured Notes, the “Unsecured Notes”), which were offered in a private offering (the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.